Podcast Episodes

Back to Search
Episode 203: What's next for Roche, a debate over second boosters, & Vertex's recent success
Episode 203: What's next for Roche, a debate over second boosters, & Vertex's recent success

What's on tap for Roche and its closely followed cancer immunotherapy? Are we all headed for another jab with a Covid-19 vaccine? And what explains t…

4 years, 6 months ago

Short Long
View Episode
Introducing: Color Code
Introducing: Color Code

As long as there's been a medical system, it's been one that is rife with instances of mistreatment — both on the individual and community levels — t…

4 years, 7 months ago

Short Long
View Episode
Episode 202: Helen Branswell on the pandemic, plus the next FDA debate & the perks of being a CEO
Episode 202: Helen Branswell on the pandemic, plus the next FDA debate & the perks of being a CEO

Are Covid-19 vaccines a sustainable business? Was Aduhelm an aberration? And what comes after Omicron? Senior writer Helen Branswell joins us to disc…

4 years, 7 months ago

Short Long
View Episode
Episode 201: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas
Episode 201: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas

How should pharma treat Russia? Why can't Congress pass a drug pricing bill? And what does wastewater portend for the pandemic? First, we discuss the…

4 years, 7 months ago

Short Long
View Episode
Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV
Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV

Can biotech companies age gracefully? Where did Covid-19 come from? And does Theranos make for good television? We cover all that and more this week.…

4 years, 7 months ago

Short Long
View Episode
Episode 199: Biden's plans for Covid pills, the latest vaccine data, & fighting about CRISPR
Episode 199: Biden's plans for Covid pills, the latest vaccine data, & fighting about CRISPR

Is "test to treat" too good to be true? Does it really matter who gets credit for CRISPR? And what's the offramp for Covid-19? We cover all that and…

4 years, 7 months ago

Short Long
View Episode
Episode 198: Medical racism, new Covid vaccines, & the resilience of Regeneron
Episode 198: Medical racism, new Covid vaccines, & the resilience of Regeneron

How many Covid-19 vaccines does the world really need? What will it take to address inequality in American health care? And should people be nicer to…

4 years, 8 months ago

Short Long
View Episode
Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay
Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay

Will there be a new ALS drug this year? What business does Wall Street have with CRISPR? And when can kids get Covid-19 vaccines? We cover all that a…

4 years, 8 months ago

Short Long
View Episode
Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic
Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic

Does Big Science have a bullying problem? Why did the FDA change its tune on China? And what's cooler than $100 billion? We cover all that and more t…

4 years, 8 months ago

Short Long
View Episode
Episode 195: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids
Episode 195: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids

Does President Biden care about the FDA? What can aerobics instructors teach us about genetics? And when can kids get Covid-19 vaccines? STAT Washing…

4 years, 8 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us